# A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

> **NCT05344469** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 800 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **OTHER:** ofatumumab
- **OTHER:** glatiramer acetate
- **OTHER:** interferon β1
- **OTHER:** teriflunomide
- **OTHER:** dimethyl fumarate (DMF)
- **OTHER:** diroximel fumarate (DRF)

## Key facts

- **NCT ID:** NCT05344469
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-10
- **Primary completion:** 2029-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05344469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05344469, "A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05344469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*